This filing is administrative and contains no new financial data or guidance. Monitor next quarterly report for any operational updates or pipeline catalysts. The equity plan increase is a non-event for near-term trading.
Price Chart
Executive Summary
Ocular Therapeutix filed an 8-K reporting the formal appointment of Jason Robins as CFO (previously interim) and stockholder approval of a 10,000,000-share increase to the 2021 Stock Incentive Plan at the 2026 Annual Meeting. The CFO appointment is a routine transition with no red flags, and the equity plan increase is standard for a biotech. No material financial data or guidance was provided.
Key Facts
- Jason Robins appointed CFO on June 10, 2026, after serving as interim CFO since January 20, 2026.
- Robins' annual base salary increased to $535,100 effective July 1, 2026, with a target bonus of 45% of base salary.
- Robins received a stock option for 14,024 shares and an RSU award for 15,441 shares, both subject to vesting.
- Stockholders approved Amendment No. 5 to the 2021 Stock Incentive Plan, increasing authorized shares by 10,000,000.
- All five stockholder proposals at the 2026 Annual Meeting passed, including election of directors and ratification of PwC as auditor.
Financial Impact
No material financial impact. CFO compensation is routine; equity plan increase of 10M shares is standard for ongoing incentive compensation.
Risk Factors
- Potential dilution from 10M additional shares under the equity plan, though typical for a biotech of this size.
- No financial results or guidance provided in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-073496 |
| Document: 0001104659-26-073496-index-headers.html | 0001104659-26-073496 |
| Document: 0001104659-26-073496-index.html | 0001104659-26-073496 |
| Document: 0001104659-26-073496.txt | 0001104659-26-073496 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | Insider Cluster | $10.90 $7.67 | ▼ −29.63% | ▼ −29.30% | $6.96 (−36.15%) |
Aug 26, 2026 5w ago | Insider Cluster | $10.82 $9.82 | ▼ −9.24% | ▼ −8.73% | $6.96 (−35.67%) |
Aug 3, 2026 8w ago | 8-K | $8.40 $10.49 | ▲ +24.88% | ▲ +23.64% | $6.96 (−17.14%) |
Jun 17, 2026 15w ago | Press Release | $9.64 $9.17 | ▼ −4.93% | ▼ −6.24% | $6.96 (−27.80%) |
Jun 12, 2026 16w ago | 8-K | $8.99 $9.88 | ▲ +9.90% | ▲ +10.65% | $6.96 (−22.58%) |
Jun 4, 2026 17w ago | Press Release | $8.80 $9.64 | ▲ +9.55% | ▲ +10.92% | $6.96 (−20.91%) |
May 28, 2026 18w ago | Insider Cluster | $9.01 $9.90 | ▲ +9.88% | ▲ +11.67% | $6.96 (−22.75%) |
May 5, 2026 21w ago | 8-K | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
May 5, 2026 21w ago | Press Release | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
Apr 30, 2026 22w ago | DEFA14A | $9.43 $8.93 | ▼ −5.30% | ▼ −10.57% | $6.96 (−26.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access